What is Biorithm?
Biorithm is a medical technology company dedicated to advancing maternal healthcare through its proprietary femom platform. This advanced system provides comprehensive remote monitoring for pregnant women, enabling healthcare providers to closely track maternal and fetal well-being. The platform also offers expectant mothers convenient access to care and vital information, fostering better engagement and continuity. Founded by a team of medical professionals and engineers, Biorithm leverages cutting-edge digital health technologies and data science to improve pregnancy outcomes and support clinicians in managing high-risk pregnancies. The company's focus on clinical investigation highlights its commitment to evidence-based innovation and patient-centric care.
How much funding has Biorithm raised?
Biorithm has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2023): $3.5M with participation from Seeds Capital
Key Investors in Biorithm
Seeds Capital
Seeds Capital is an entity operating within the Electricity, Oil & Gas industry, headquartered in the United Kingdom. Its participation in this funding round suggests a potential interest in the intersection of technology and healthcare infrastructure or a diversified investment strategy.
What's next for Biorithm?
With the recent major strategic investment, Biorithm is poised to accelerate the development and deployment of its femom platform. This funding is expected to fuel further clinical validation, enhance the platform's capabilities, and expand its reach within the healthcare ecosystem. The company's focus on improving maternal and fetal health outcomes aligns with a critical need in global healthcare, suggesting a strong trajectory for growth and adoption as they move beyond the clinical investigation phase and towards broader market penetration. The strategic nature of this investment indicates potential partnerships and collaborations that could further solidify Biorithm's position in the digital health landscape.
See full Biorithm company page
